Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07698548Not ApplicableNot Yet Recruiting

Fuyang Jiedu Granules Plus Antiretroviral Therapy for HIV Immune Non-Responders With Spleen-Kidney Yang Deficiency

Role: collaborator

NCT07608172Not ApplicableNot Yet Recruiting

Short-Course Regimens for DS-PTB in AIDS Patients

Role: collaborator

NCT05129904Active Not Recruiting

Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)

Role: collaborator

NCT07565623Not ApplicableNot Yet Recruiting

Prevention of AIDS With Opportunistic Infection Paradoxical IRIS

Role: collaborator

All 4 trials loaded